---
title: "CVS beats Q3 revenue, profit estimates, outlook raised; to split into two"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304267521.md"
datetime: "2026-11-04T11:41:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304267521.md)
  - [en](https://longbridge.com/en/news/304267521.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304267521.md)
generator: "portal-rs"
---

# CVS beats Q3 revenue, profit estimates, outlook raised; to split into two

) Overview

-   US health solutions firm’s Q3 revenue rose 5.4%, beating analyst expectations
-   Q3 adjusted EPS increased to $2.09, beating analyst expectations
-   Company raised full-year 2026 guidance for EPS and cash flow from operations
-   CVS to split in two, separating pharmacy business from insurance Outlook
-   CVS raises full-year 2026 GAAP diluted EPS guidance to at least $6.98 from $6.84-$7.04
-   Company lifts 2026 adjusted EPS guidance to at least $8.20 from $7.90-$8.10
-   CVS increases 2026 cash flow from operations guidance to at least $15.5 bln from $11.5 bln Result Drivers
-   HEALTH SERVICES GROWTH - Revenue in the Health Services segment rose 9.5%, driven by pharmacy drug mix and brand inflation, partly offset by pharmacy client price improvements
-   HEALTH CARE BENEFITS IMPROVEMENT - Adjusted operating income in the Health Care Benefits segment rose, mainly due to improved performance in the Government business
-   RETAIL PHARMACY PRESSURE - Pharmacy & Consumer Wellness revenue fell 2.0% due to regulatory-related price reductions, new generic drug introductions, and reimbursement pressure, partly offset by increased prescription volume and brand inflation Company press release: Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $108.40 $104.69

Revenue bln bln (19

Analysts

)

Q3 Beat $2.09 $1.65

Adjusted (24

EPS Analysts

)

Q3 EPS $1.68 Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 25 “strong buy” or “buy”, 4 “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the healthcare facilities & services peer group is “buy”
-   Wall Street’s median 12-month price target for CVS Health Corporation is $112.00, about 22.5% above its November 3 closing price of $91.41
-   The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 13 three months ago Reuters Recommended Reads
-   Nov 3 - CVS Health explores splitting retail pharmacy, insurance businesses, FT reports
-   Nov 3 - Senior care provider InnovAge’s Q1 revenue beats as participants increase
-   Nov 3 - Addus HomeCare Q3 adjusted EPS beats estimates; to acquire AccentCare personal care division For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [CVS.US](https://longbridge.com/en/quote/CVS.US.md)
- [ADUS.US](https://longbridge.com/en/quote/ADUS.US.md)
- [INNV.US](https://longbridge.com/en/quote/INNV.US.md)

## Related News & Research

- [CVS Health plans to split itself up. Here's why a breakup could make sense now](https://longbridge.com/en/news/304328074.md)
- [CVS announces major breakup, pharmacy expert weighs impact on consumers](https://longbridge.com/en/news/304442551.md)
- [CVS Health Raises Its Outlook, Confirms Massive Breakup](https://longbridge.com/en/news/304322300.md)
- [BREAKINGVIEWS-CVS’s problem: investors trust the warning label](https://longbridge.com/en/news/304320828.md)
- [CVS Raises Forecast on Health Care Benefits, Pharmacy Gains](https://longbridge.com/en/news/304271451.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**